. 2017 Jan 25;9(3):183–187. doi: 10.14740/jocmr2653w

Table 1. Patient Characteristics Before Radiotherapy (RT) and Survival Outcomes (n = 118).

Parameter	n	%	Median survival, months	P-value
Estrogen receptor (ER) positive	91	77	15.6
Estrogen receptor (ER) negative	27	23	5.8	0.004
HER2 positive^a	20	18	14.4
HER2 negative^a	90	82	12.4	0.65
Triple negative^a	22	20	5.5
ER positive HER2 negative^a	68	62	15.5
ER negative HER2 positive^a	5	5	11.4
ER and HER2 positive^a	15	14	15.9	0.007^b
Metastases at first diagnosis^a	17	15	6.9
Metachronous metastatic disease^a	98	85	14.7	0.13
Interval from metastatic disease to RT ≤ 1 month^a	32	28	17.6
Interval from metastatic disease to RT 2 - 6 months^a	24	21	13.9
Interval from metastatic disease to RT 7 - 12 months^a	14	12	7.5
Interval from metastatic disease to RT 13 - 59 months^a	35	30	9.0
Interval from metastatic disease to RT ≥ 60 months^a	10	9	9.0	0.02^b
No extra-skeletal visceral metastases	57	48	22.9
One site of visceral metastases, e.g. lung(s)	43	36	8.2
More than one site of visceral metastases	18	15	5.1	0.0001^b
Liver metastases	36	31	7.3	0.0001
Lung metastases	38	32	7.3	0.004
Pleural metastases/effusion	19	16	3.9	0.0001
Brain metastases	4	3	3.4	0.0001
ECOG PS 0	32	27	27.3
ECOG PS 1	38	32	15.6
ECOG PS 2	32	27	10.3
ECOG PS 3 - 4	16	14	3.1	0.0001^b
Received no previous RT	26	22	14.9
One previous course	51	43	16.9
At least two previous courses	41	35	9.0	0.01^b
Serum albumin normal^a	94	84	15.5
Serum albumin low^a	18	16	5.1	0.001
Serum LDH normal^a	45	45	27.0
Serum LDH high^a	56	55	6.9	0.0001
Serum ALP normal^a	47	45	21.1
Serum ALP high^a	58	55	9.0	0.0001
Serum CRP normal^a	55	50	22.9
Serum CRP high (≤ 30)^a	29	26	12.7
Serum CRP high (31 - 60)^a	13	12	5.8
Serum CRP high (> 60)^a	14	13	5.0	0.0001^b
Hemoglobin normal^a	80	71	15.9
Hemoglobin low^a	33	29	8.2	0.004
Received blood transfusion before RT	9	8	9.0	0.01
CA 15-3 normal^a	14	16	36.2
CA 15-3 high^a	75	84	12.2	0.007

^aInformation not available in all patients. ^bP-value calculated over all strata. ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: lactate dehydrogenase; ALP: alkaline phosphatase; CRP: C-reactive protein.